{"result": {"id": "chatcmpl-222", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "The **patients** in the study are individuals affected by various conditions, including NANFH, asymptomatic carotid plaque, diabetes, unilateral treatment-naïve exudative neovascular age-related macular degeneration (nAMD), and those with CF-LVADs.  They also include people diagnosed with AMD and those experiencing corneal neovascularization, lipid keratopathy, or proliferative retinopathy. The study focuses on **patients** who have had ischemic strokes and received anti-VEGF injections, resulting in varying responses. Some of these patients are specifically those with SC hemoglobinopathy and CCRC, while others may be individuals with a history of ischemic stroke.  The study utilizes consecutive patients for analysis, allowing for a comprehensive understanding of the impact of various conditions on **patients**. \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743328174, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 157, "prompt_tokens": 298, "total_tokens": 455, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"PATIENTS\"\nDescription List: [\"23 patients with HM and mCNV received IVIs\", \"Consecutive patients were studied\", \"Individuals who have had an ischemic stroke\", \"Individuals with SC hemoglobinopathy and proliferative retinopathy\", \"Individuals with corneal neovascularization and lipid keratopathy\", \"Patients are those affected by the condition of NANFH\", \"Patients in the study\", \"Patients undergoing treatment\", \"Patients who received anti-VEGF injections and showed varying responses\", \"Patients with CCRC\", \"Patients with asymptomatic carotid plaque\", \"Patients with diabetes\", \"Patients with unilateral treatment-naïve exudative neovascular age-related macular degeneration (nAMD)\", \"People who have CF-LVADs\", \"People who have been diagnosed with AMD\", \"People with choroidal neovascularization\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_4bd5fc6f9a9d33b502ee5a5f2cfd418a2ffd1c7faa235adb2b61d064c2c6c31b_v2"}